Topics

Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines

04:32 EDT 4 Oct 2019 | Pharmaceutical Business Review

The company was founded on computationally designed self-assembling virus-like particle (VLP) technology developed at the Institute for Protein Design (IPD) at University of Washington School of Medicine (Cell

The post Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines appeared first on Pharmaceutical Business review.

Original Article: Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines

NEXT ARTICLE

More From BioPortfolio on "Icosavax launches with $51m Series A financing to advance computationally designed VLP vaccines"

Quick Search